Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 502 Results

Page 30 of 51« First «...10 20...28 293031 32...40 50...»Last »

January 3, 2018

DBV Technologies to Present at the 36th Annual J.P. Morgan Healthcare Conference

December 4, 2017

DBV Technologies CEO, Chairman, and Co-Founder, Dr. Pierre-Henri Benhamou Recognized for His Lasting Impact on the Food Allergy Community and Research Advancement by FARE (Food Allergy Research & Education)

November 28, 2017

DBV Technologies to Attend Citi’s 2017 Global Healthcare Conference

November 20, 2017

DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients

November 14, 2017

DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut inthe Journal of the American Medical Association

October 31, 2017

DBV Technologies Reports September 30, 2017 Cash Position

October 20, 2017

DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age

October 12, 2017

DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut

October 12, 2017

DBV Technologies Announces Completion of Blinded Period in REALISE Study of Viaskin Peanut

September 1, 2017

DBV Technologies to Attend Upcoming Investor Conferences

Page 30 of 51« First «...10 20...28 293031 32...40 50...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Cookies Policy

Scroll to Top